Biogen's Alzheimer's Drug Is Not Doing Well

Biogen's Alzheimer's Drug Is Not Doing Well
(Biogen via AP, File)

Since the FDA approved Biogen's aducanumab (brand name Aduhelm) as an antibody for Alzheimer's therapy - a decision I thought was a ruinous mistake - we've been seeing some unprecedented things play out. The decision itself remains controversial, and three members of the advisory committee that recommended strongly against approval have resigned in protest.

Read Full Article »


Comment
Show comments Hide Comments


Related Articles